10,251
Participants
Start Date
September 30, 1999
Primary Completion Date
June 30, 2009
Study Completion Date
December 31, 2012
Anti-hyperglycemic Agents
Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
Anti-hypertensive Agents
Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
Blinded fenofibrate or placebo plus simvastatin
Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
Columbia University, New York
Wake Forest University, Winston-Salem
Veterans Affairs, Memphis
Case Western Reserve University, Cleveland
Minneapolis Medical Research Foundation, Minneapolis
University of Washington, Seattle
McMaster University, Hamilton
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
National Institute on Aging (NIA)
NIH
National Eye Institute (NEI)
NIH
Centers for Disease Control and Prevention
FED
National Heart, Lung, and Blood Institute (NHLBI)
NIH